---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016857"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:02:15.576511+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio doses first SCD patient with nula-cel; Q2 net loss $25.9M, cash $328.3M

## Summary
- Dosed first patient in Phase 1/2 CEDAR trial of nula-cel for sickle cell disease; initial proof-of-concept data expected mid-2023.
- Cash, cash equivalents and marketable securities of $328.3M as of June 30, 2022; cash runway into Q4 2024.
- Q2 2022 net loss of $25.9M ($0.48 per share); R&D expenses $17.8M, G&A $9.0M.
- Nula-cel received FDA Fast Track designation for SCD; also has Orphan Drug designation.
- Preclinical data for GPH102 in beta-thalassemia presented at ASGCT; IND planned by mid-2024.

## SEC filing metadata
- accession: 0000950170-22-016857
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000095017022016857/0000950170-22-016857-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000095017022016857/grph-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016857
- JSON: https://secwatch.observer/filing/0000950170-22-016857.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016857.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.